DOCSLIB.ORG

2015 CSBPR MCF Table 1B Antidepressant Overview June 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table 1B: Overview of Antidepressant Therapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on select medications identified through the evidence reviews as the most frequently used medications for the management of post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, side effects, drug interactions and comorbidities should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Serotonin–norepinephrine Other Reuptake Inhibitors (SSRI) reuptake inhibitors (SNRI) Medication citalopram – Celexa duloxetine - Cymbalta methylphenidate – Ritalin Generic and escitalopram – Cipralex milnacipran – not available in Canada (amphetamine) Trade Names fluoxetine – Prozac reboxetine – special access program nortriptyline – Aventyl (tricyclic fluvoxamine - Luvox only antidepressant) paroxetine – Paxil venlafaxine – Effexor trazodone – Desyrel, PMS-, Apo-, sertraline - Zoloft Dom-, Mylan-, Nu-, Phl-, ratio-, Teva- trazodone (tetracylic antidepressant) Contra- Fluoxetine – intracranial hemorrhage Hypersensitivity, patients with a Nortriptyline – cardiac abnormalities indications seizure disorder, or taking MAOIs Hypersensitivity, patients with All- Hypersensitivity to SSRIs, or uncontrolled narrow angle glaucoma, taking Monoamine oxidase inhibitors or patients taking: MAOIs, certain (MAOIs) antibiotics , CYP1A2 inhibitors (eg. fluvoxamine and quinolones) Side Effects SSRI: Serotonin syndrome, sedation, Venlafaxine - Increases in heart rate nortriptyline – may increase risk of increased risk for seizures (0.2% can occur by 3-4bpm, QTc delirium in stroke patients; serotonin incidence), bleeding, and arrhythmia at 75-225mg/day. syndrome, ventricular arrhythmias hyponatremia and orthostatic hypotension Duloxetine - been associated with fluoxetine: interacts with certain an increase in blood pressure and Generally reported: dry mouth, loss cardiac medication e.g. clopidogrel clinically significant hypertension in of appetite and weight-loss, loss of most severely, nimodipline, and some patients libido, constipation, nausea, beta-blockers dizziness, anxiety, somnolence, Generally reported: dry mouth, loss sweating Generally reported: dry mouth, loss of appetite and weight-loss, loss of of appetite and weight-loss, nausea, libido, constipation, nausea, dizziness, loss of libido, constipation insomnia, dizziness or diarrhea, insomnia or somnolence, anxiety, sweating CSBPR Fifth Edition June 2015 Page 1 of 9 Heart and Stroke Foundation Mood, Cognition and Fatigue Following Stroke Canadian Stroke Best Practice Recommendations Pharmacotherapy for Post-Stroke Depression Selective Serotonin Serotonin–norepinephrine Other Reuptake Inhibitors (SSRI) reuptake inhibitors (SNRI) sweating Landmark citalopram6,14, fluvoxamine8 , reboxetine10 , milnacipran11, trazodone15,16 , nortriptyline17,18 Trials fluoxetine 1-5,14 sertraline7,14 venlafaxine12 , duloxetine14 methylphenidate19 paroxetine9 Inclusion / First ever and recurrent strokes SNRI: PSD following from first ever First ever and recurrent strokes Exclusion stroke. Criteria & Mild depression5, 7, 8 trazodone: mild15 and moderate16 Depression Moderate depression1,2,4,5,6 Reboxetine: only severe “retarded depression severity Severe depression 3, 9, 14 depression” in first ever stroke. nortriptyline: mild17 and moderate18 Milnacipran: mild depression, prior depression depression or antidepressant use was excluded. methylphenidate: moderate Venlafaxine: moderate depression depression Duloxetine: severe depression Dose ranges fluoxetine: 10 - 40mg /day (including venlafaxine: 75 – 150 mg/day trazodone: 200 – 300mg/day tested variable dose study)citalopram: 20 – reboxetine: 4mg/ 2x day mirtazepine: 30mg/day 60mg/ day milnacipran: 50 – 100mg/day nortriptyline: 20 – 100mg/day escitalopram: 10 – 20mg/day duloxetine: 60 – 120mg/day sertraline: 50 - 100mg/day Summary of mild: 1 negative, 1 positive studies mild: 2 positive studies mild: 2 positive studies Findings moderate: 2 negative, 3 positive moderate: 1 positive studies moderate: 3 positive studies studies severe: 1 positive studies severe: no studies severe: 1 negative, 3 positive studies Studies were open-label or uncontrolled; no level 1 RCT Level 1 RCT evidence available to Level 1 RCT evidence supports the evidence available to support efficacy support nortriptyline and efficacy of SSRIs fluoxetine and of SNRI for treatment of post-stroke methylphenidate for treatment of citalopram for treatment of moderate depression. post-stroke depression. to severe post-stroke depression. Other Prevention of PSD: fluoxetine, Anxiety in PSD: duloxetine more Mortality & PSD: increased survival Outcomes escitalopram and sertraline studied effective than citalopram in treating of depressed and non-depressed CSBPR Fifth Edition June 2015 Page 2 of 9 Heart and Stroke Foundation Mood, Cognition and Fatigue Following Stroke Canadian Stroke Best Practice Recommendations Pharmacotherapy for Post-Stroke Depression Selective Serotonin Serotonin–norepinephrine Other Reuptake Inhibitors (SSRI) reuptake inhibitors (SNRI) as prophylaxis anxiety symptoms treated with fluoxetine or nortriptyline over placebo in 9-year follow-up3 Mortality & PSD: increased survival Alexithymia: venlafaxine results in of depressed and non-depressed greater improvement of emotional Functional status (ADLs): trazodone treated with fluoxetine or nortriptyline awareness than fluoxetine treatment resulted in trending over placebo in 9-year follow-up1 improvement Executive function: maintenance of executive function compared to placebo over 21 months follow-up2; no improvement of executive function Sleep: fluvoxamine improved sleep disturbances as measured by peripheral melatonin blood levels. Safety Discontinuation: Discontinuation of Duloxetine: should be used with Trazodone: serious warning for escitalopram may increase caution in patients with uncontrolled priapism, associated with increased poststroke depressive symptoms hypertension as it may expose them risk of syncope and falls, particularly over 6 months4 to hypertensive crisis in older patients Cerebrovascular AE: rare (<1/1000) Nortriptyline: special consideration in fluoxetine, infrequent to rare (1/100 for geriatric population with to 1/1000) for other SSRIs but orthostatic hypotension and vigilance required for use in high-risk anticholinergic effects; caution is bleeding & vasoconstrictive stroke.5 advised if used in patients with a personal or family history of Geriatric: anticholinergic effects and cardiovascular disease, arrhythmias orthostatic hypotension can be or conduction disturbances particularly problematic in older patients, resulting in increased risk of i Jorge, Am J Psychiatry 2003 Oct;160(10):1823-9 2 Narushima, B J Psych 2007, 190:260-265 3 Jorge, Am J Psychiatry 2003 Oct;160(10):1823-9 4 Mikami, Stroke 2011; Aug 42:3281-3283 5 Ramasubbu, J Clin Psychiatry 2004; 64:1642-1653 CSBPR Fifth Edition June 2015 Page 3 of 9 Heart and Stroke Foundation Mood, Cognition and Fatigue Following Stroke Canadian Stroke Best Practice Recommendations Pharmacotherapy for Post-Stroke Depression Selective Serotonin Serotonin–norepinephrine Other Reuptake Inhibitors (SSRI) reuptake inhibitors (SNRI) cognitive impairment, confusion, urinary retention and falls. Delirium : anticholinergic effects may play role in delirium in acute stroke patients6 $ per month/ citalopram $0.33/day (regular benefit) duloxetine – Cymbalta (30mg) $1.89 methylphenidate – $0.28-$4.18 (10- coverage in escitalopram $1.84 (regular benefit) and (60mg) $3.79 80mg) Canada fluoxetine (20mg) $0.46 (regular milnacipran – not available trazodone ~$0.10/day (regular benefit) reboxetine - not readily available, not benefit) paroxetine – (20mg) $0.45 and covered by provincial drug coverage (30mg) $0.4796 plans sertraline - (25mg) $0.20 and venlafaxine $0.3469/day (regular ~(100mg) $0.40 benefit) fluvoxamine - (50mg) $0.21 and (100mg) $0.38 6 Caeiro, Eur J. of Neurology 2004; 11: 699–704 CSBPR Fifth Edition June 2015 Page 4 of 9 Appendix One: Pharmacotherapy Trials Ref Class Drug Reference Patients Depression Severity Treatment Dose Drop- +/- Finding AEs of No. (Treated/ (Treated/Control) (wks) (mg/day) out treated Control) group Fluoxetine improvement in Cravello moderate; baseline 1 SSRI (randomized, 25 8 20-40 + depressive symptoms (2009) ‡ HAM-D: 19; uncontrolled) similar to venlafaxine not significant on PSD, 10 AE, 1 Choi-Kwon moderate; baseline but improvements 2 SSRI Fluoxetine 76/76 12 20 15/76 - hospitalizatio (2006) BDI: 19 observed in emotional n disturbances non-significant over placebo in 3 months, Freuhwald severe; baseline significant lowered none 3 SSRI Fluoxetine 28/ 26 12 20-40 4/50 - (2003) HAM-D: 33/30 depression at 18 detected months open-label follow-up no significant Weight loss, Robinson moderate; baseline differences between Anxiety, 4 SSRI Fluoxetine 23 / 17 12 10-40 13/23 - (2000) HAM-D: 20/18 fluoxetine and placebo Insomnia in depression GI symptoms significant 1 AE of moderate; MDD by improvement in transient increase of Wiart ICD-10 and MADRS depression 5 SSRI Fluoxetine 16/15 6.5 20 2/31 + transaminase (2000) ≥ 19; baseline s; MADRS: 29/27 well- tolerated significant reduction of depression,
Recommended publications
  • Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V

    Concomitant Drugs Associated with Increased Mortality for MDMA Users Reported in a Drug Safety Surveillance Database Isaac V

    www.nature.com/scientificreports OPEN Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Isaac V. Cohen1, Tigran Makunts2,3, Ruben Abagyan2* & Kelan Thomas4 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug– drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings. 3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Adminis- tration (FDA) for the treatment of posttraumatic stress disorder (PTSD). During the past two decades, “ecstasy” was illegally distributed and is purported to contain MDMA, but because the market is unregulated this “ecstasy” may actually contain adulterants or no MDMA at all1.
  • Canadian Stroke Best Practice Recommendations

    Canadian Stroke Best Practice Recommendations

    CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS MOOD, COGNITION AND FATIGUE FOLLOWING STROKE Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression Update 2019 Lanctôt KL, Swartz RH (Writing Group Chairs) on Behalf of the Canadian Stroke Best Practice Recommendations Mood, Cognition and Fatigue following Stroke Writing Group and the Canadian Stroke Best Practice and Quality Advisory Committee, in collaboration with the Canadian Stroke Consortium © 2019 Heart & Stroke Heart and Stroke Foundation Mood, Cognition and Fatigue following Stroke Canadian Stroke Best Practice Recommendations Table 1C Table 1C: Summary Table for Selected Pharmacotherapy for Post-Stroke Depression This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on selected classes of medications available for use in Canada and more commonly recommended for post-stroke depression. This table should be used as a reference guide by health care professionals when selecting an appropriate agent for individual patients. Patient compliance, patient preference and/or past experience, side effects, and drug interactions should all be taken into consideration during decision-making, in addition to other information provided in this table and available elsewhere regarding these medications. Selective Serotonin Reuptake Inhibitors (SSRI) Serotonin–norepinephrine reuptake Other inhibitors (SNRI) Medication *citalopram – Celexa *duloxetine – Cymbalta methylphenidate – Ritalin (amphetamine)
  • Methylphenidate Hydrochloride

    Methylphenidate Hydrochloride

    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
  • Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 for Drugs Not Found on This List, Go to the Drug Search Engine At

    Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 for Drugs Not Found on This List, Go to the Drug Search Engine At

    Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com *Exceptions as noted above* ▪ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪Budesonide: Prior authorization NOT required for participants age 7 years and under ▪Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪Antipsychotics: Prior authorization required for participants under 8 years of age and long- term care residents 1 of 27 Preferred Drug List Illinois Medicaid 10/1/2019: Revised 11/06/2019 For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Category Preferred Preferred, Requires PA Non-Preferred ADHD Agent - Amphetamine Mixtures* AMPHETAMINE/DEXTROAMPHETAMINE ADDERALL ADDERALL XR MYDAYIS ADHD Agent - Amphetamines* VYVANSE ADZENYS ER ADZENYS XR-ODT AMPHETAMINE SULFATE DESOXYN DEXEDRINE DEXTROAMPHETAMINE SULFATE DEXTROAMPHETAMINE SULFATE ER DYANAVEL XR EVEKEO EVEKEO ODT METHAMPHETAMINE HCL PROCENTRA ZENZEDI ADHD Agent - Selective Alpha Adrenergic Agonists CLONIDINE HCL ER INTUNIV CLONIDINE HYDROCHLORIDE ER GUANFACINE ER ADHD Agent - Selective Norepinephrine Reuptake Inhibitor* ATOMOXETINE ATOMOXETINE HYDROCHLORIDE STRATTERA 2 of 27 Preferred Drug List Illinois
  • Levomilnacipran (Fetzima®) Indication

    Levomilnacipran (Fetzima®) Indication

    Levomilnacipran (Fetzima®) Indication: Indicated for the treatment of major depressive disorder (MDD), FDA approved July 2013. Mechanism of action Levomilnacipran, the more active enantiomer of racemic milnacipran, is a selective SNRI with greater potency for inhibition of norepinephrine relative to serotonin reuptake Compared with duloxetine or venlafaxine, levomilnacipran has over 10-fold higher selectivity for norepinephrine relative to serotonin reuptake inhibition The exact mechanism of the antidepressant action of levomilnacipran is unknown Dosage and administration Initial: 20 mg once daily for 2 days and then increased to 40 mg once daily. The dosage can be increased by increments of 40 mg at intervals of two or more days Maintenance: 40-120 mg once daily with or without food. Fetzima should be swallowed whole (capsule should not be opened or crushed) Levomilnacipran and its metabolites are eliminated primarily by renal excretion o Renal impairment Dosing: Clcr 30-59 mL/minute: 80 mg once daily Clcr 15-29 mL/minute: 40 mg once daily End-stage renal disease (ESRD): Not recommended Discontinuing treatment: Gradually taper dose, if intolerable withdrawal symptoms occur, consider resuming the previous dose and/or decrease dose at a more gradual rate How supplied: Capsule ER 24 Hour Fetzima Titration: 20 & 40 mg (28 ea) Fetzima: 20 mg, 40 mg, 80 mg, 120 mg Warnings and Precautions Elevated Blood Pressure and Heart Rate: measure heart rate and blood pressure prior to initiating treatment and periodically throughout treatment Narrow-angle glaucoma: may cause mydriasis. Use caution in patients with controlled narrow- angle glaucoma Urinary hesitancy or retention: advise patient to report symptoms of urinary difficulty Discontinuation Syndrome Seizure disorders: Use caution with a previous seizure disorder (not systematically evaluated) Risk of Serotonin syndrome when taken alone or co-administered with other serotonergic agents (including triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, and St.
  • Levomilnacipran for the Treatment of Major Depressive Disorder

    Levomilnacipran for the Treatment of Major Depressive Disorder

    Out of the Pipeline Levomilnacipran for the treatment of major depressive disorder Matthew Macaluso, DO, Hala Kazanchi, MD, and Vikram Malhotra, MD An SNRI with n July 2013, the FDA approved levomil- Table 1 once-daily dosing, nacipran for the treatment of major de- Levomilnacipran: Fast facts levomilnacipran pressive disorder (MDD) in adults.1 It is I Brand name: Fetzima decreased core available in a once-daily, extended-release formulation (Table 1).1 The drug is the fifth Class: Serotonin-norepinephrine reuptake symptoms of inhibitor serotonin-norepinephrine reuptake inhibi- MDD and was well Indication: Treatment of major depressive tor (SNRI) to be sold in the United States disorder in adults tolerated in clinical and the fourth to receive FDA approval for FDA approval date: July 26, 2013 trials treating MDD. Availability date: Fourth quarter of 2013 Levomilnacipran is believed to be the Manufacturer: Forest Pharmaceuticals more active enantiomer of milnacipran, Dosage forms: Extended–release capsules in which has been available in Europe for 20 mg, 40 mg, 80 mg, and 120 mg strengths years and was approved by the FDA in Recommended dosage: 40 mg to 120 mg 2009 for treating fibromyalgia. Efficacy of capsule once daily with or without food levomilnacipran for treating patients with Source: Reference 1 MDD was established in three 8-week ran- domized controlled trials (RCTs).1 cial and occupational functioning in addi- Clinical implications tion to improvement in the core symptoms Levomilnacipran is indicated for treating of depression.5
  • Sibutramine Hydrochloride Monohydrate) Capsule CS-IV

    Sibutramine Hydrochloride Monohydrate) Capsule CS-IV

    MERIDIA - sibutramine hydrochloride capsule ---------- MERIDIA® (sibutramine hydrochloride monohydrate) Capsule CS-IV DESCRIPTION MERIDIA® (sibutramine hydrochloride monohydrate) is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of the (+) and (-) enantiomers of cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate, and has an empirical formula of C17H29Cl2NO. Its molecular weight is 334.33. The structural formula is shown below: Sibutramine hydrochloride monohydrate is a white to cream crystalline powder with a solubility of 2.9 mg/mL in pH 5.2 water. Its octanol: water partition coefficient is 30.9 at pH 5.0. Each MERIDIA capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients]. CLINICAL PHARMACOLOGY Mode of Action Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. Pharmacodynamics Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin (5- hydroxytryptamine, 5-HT) and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo.
  • Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex

    Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex

    Title Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Author(s) Tsutsui-Kimura, Iku; Yoshida, Takayuki; Ohmura, Yu; Izumi, Takeshi; Yoshioka, Mitsuhiro International journal of neuropsychopharmacology, 18(5), pyu083 Citation https://doi.org/10.1093/ijnp/pyu083 Issue Date 2015-03 Doc URL http://hdl.handle.net/2115/59283 Rights(URL) http://creativecommons.org/licenses/by-nc/4.0 Type article File Information pyu083.full.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP International Journal of Neuropsychopharmacology, 2015, 1–14 doi:10.1093/ijnp/pyu083 Research Article research article Milnacipran Remediates Impulsive Deficits in Rats with Lesions of the Ventromedial Prefrontal Cortex Iku Tsutsui-Kimura, PhD; Takayuki Yoshida, PhD; Yu Ohmura, PhD; Takeshi Izumi, MD, PhD; Mitsuhiro Yoshioka, MD, PhD Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Sapporo, Japan (Drs Tsutsui-Kimura, Yoshida, Ohmura, Izumi, and Yoshioka); Japan Society for the Promotion of Science, Tokyo, Japan (Dr Tsutsui-Kimura); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Dr Tsutsui-Kimura). Correspondence: Yu Ohmura, PhD, Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo, 060-8638, Japan ([email protected]). Abstract Background: Deficits in impulse control are often observed in psychiatric disorders in which abnormalities of the prefrontal cortex are observed, including attention-deficit/hyperactivity disorder and bipolar disorder. We recently found that milnacipran, a serotonin/noradrenaline reuptake inhibitor, could suppress impulsive action in normal rats. However, whether milnacipran could suppress elevated impulsive action in rats with lesions of the ventromedial prefrontal cortex, which is functionally comparable with the human prefrontal cortex, remains unknown.
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology

    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology

    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
  • Milnacipran for Pain in Fibromyalgia in Adults

    Milnacipran for Pain in Fibromyalgia in Adults

    Milnacipran for pain in fibromyalgia in adults (Review) Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 10 http://www.thecochranelibrary.com Milnacipran for pain in fibromyalgia in adults (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 14 Figure5. ..................................... 18 DISCUSSION ..................................... 21 AUTHORS’CONCLUSIONS . 22 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 23 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 38 Analysis 1.1. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 1 At least 30% pain relief. 39 Analysis 1.2. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 2 PGIC ’much improved’ or ’very much improved’.................................... 40 Analysis 1.3. Comparison
  • Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults

    Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults

    Draft Comparative Effectiveness Review Number xx Adverse Effects of First-line Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy. Contract No. 290-2015-00012I Prepared by: Will be included in the final report Investigators: Will be included in the final report AHRQ Publication No. xx-EHCxxx <Month, Year> ii Purpose of the Review To assess adverse events of first-line antidepressants in the treatment of major depressive disorder in adults 65 years or older. Key Messages • Acute treatment (<12 weeks) with o Serotonin norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), but not selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine) led to a greater number of adverse events compared with placebo. o SSRIs (citalopram, escitalopram and fluoxetine) and SNRIs (duloxetine and venlafaxine) led to a greater number of patients withdrawing from studies due to adverse events compared with placebo o Details of the contributing adverse events in RCTs were rarely reported to more clearly characterize what adverse events to expect.
  • Efficacy of Milnacipran in Patients with Fibromyalgia R

    Efficacy of Milnacipran in Patients with Fibromyalgia R

    Efficacy of Milnacipran in Patients with Fibromyalgia R. MICHAEL GENDREAU, MICHAEL D. THORN, JUDY F. GENDREAU, JAY D. KRANZLER, SAULO RIBEIRO, RICHARD H. GRACELY, DAVID A. WILLIAMS, PHILIP J. MEASE, SAMUEL A. McLEAN, and DANIEL J. CLAUW ABSTRACT. Objective. Fibromyalgia (FM) is a common musculoskeletal condition characterized by widespread pain, tenderness, and a variety of other somatic symptoms. Current treatments are modestly effec- tive. Arguably, the best studied and most effective compounds are tricyclic antidepressants (TCA). Milnacipran, a nontricyclic compound that inhibits the reuptake of both serotonin and norepineph- rine, may provide many of the beneficial effects of TCA with a superior side effect profile. Methods. One hundred twenty-five patients with FM were randomly assigned in a 3:3:2 ratio to receive milnacipran twice daily, milnacipran once daily, or placebo for 3 months in a double-blind dose-escalation trial; 92% of twice-daily and 81% of once-daily participants achieved dose escala- tion to the target milnacipran dose of 200 mg. Results. The primary endpoint was reduction of pain. Both the once- and twice-daily groups showed statistically significant improvements in pain, as well as improvements in global well being, fatigue, and other domains. Response rates for patients receiving milnacipran were equal in patients with and without comorbid depression, but placebo response rates were considerably higher in depressed patients, leading to significantly greater overall efficacy in the nondepressed group. Conclusion. In this Phase II study, milnacipran led to statistically significant improvements in pain and other symptoms of FM. The effect sizes were equal to those previously found with TCA, and the drug was generally well tolerated.